Who Researches This?
Who Researches Tesofensine?
Tesofensine is researched by people exploring potent appetite suppressants for weight loss who are comparing options beyond GLP-1 agonists like semaglutide. Its triple reuptake mechanism (serotonin, norepinephrine, dopamine) distinguishes it from single-target approaches. Researchers studying monoamine neurotransmission, appetite regulation, and metabolic rate enhancement will find it relevant. Note that cardiovascular safety concerns (heart rate and blood pressure elevations) have been a regulatory hurdle.
Related Resources
- Comparisons: Tesofensine vs Semaglutide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
What Is Tesofensine?
Tesofensine was originally developed by Danish pharmaceutical company NeuroSearch A/S as a treatment for Parkinson's disease and Alzheimer's disease. During Phase 2 trials for neurological indications, researchers observed unexpectedly significant weight loss in participants — a finding that led to its redevelopment as an obesity treatment.
The compound is a small molecule (not a peptide) that inhibits presynaptic reuptake of all three monoamine neurotransmitters. By increasing synaptic concentrations of serotonin, norepinephrine, and dopamine simultaneously, it produces appetite suppression through multiple complementary pathways — more comprehensive than single-target agents like lorcaserin (serotonin only) or phentermine (norepinephrine/dopamine).
Mechanism of Action
Tesofensine inhibits the reuptake transporters for three monoamines:
- Serotonin (5-HT): Enhances satiety signaling in the hypothalamus — reduces appetite and food-seeking behavior
- Norepinephrine (NE): Increases sympathetic nervous system activity — promotes thermogenesis and energy expenditure
- Dopamine (DA): Modulates reward processing — may reduce hedonic (pleasure-based) eating and food cravings
The combined effect is both reduced caloric intake (appetite suppression) and increased caloric output (thermogenesis), producing a dual mechanism for weight loss.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
No spam · Unsubscribe anytime
Dosage Overview
Clinical trial dosing: 0.25 mg, 0.5 mg, or 1.0 mg orally once daily. The 0.5 mg dose showed the best efficacy-safety balance in Phase 2, producing ~10.6% weight loss over 24 weeks. The 1.0 mg dose showed greater weight loss (~13%) but with more cardiovascular effects.
Tesofensine is an oral capsule — no reconstitution required.
Side Effects & Safety
- Elevated heart rate: Mean increase of 7–8 bpm at therapeutic doses — the primary safety concern
- Dry mouth: Very common, related to noradrenergic activity
- Insomnia: Dopamine and norepinephrine elevation can disrupt sleep
- Constipation: Related to serotonergic effects
- Mood changes: Anxiety, irritability reported in some participants
- Blood pressure: Modest increases in some patients
The cardiovascular effects (heart rate, blood pressure) have been the primary regulatory concern and a barrier to FDA approval. Long-term cardiovascular safety data is limited.